Cart
sales@molnova.com
5-methylnonan-5-ol
CAS No. 33933-78-7
5-methylnonan-5-ol( —— )
Catalog No. M37397 CAS No. 33933-78-7
5-methylnonan-5-ol (5-methyl-5-nonanol) is an intermediate in the production of 5-nonanol-5-methyl-5-methacrylate and is a volatile substance in the endophyte MC_25L of orange leaves.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 29 | In Stock |
|
| 50MG | 37 | In Stock |
|
| 100MG | 53 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name5-methylnonan-5-ol
-
NoteResearch use only, not for human use.
-
Brief Description5-methylnonan-5-ol (5-methyl-5-nonanol) is an intermediate in the production of 5-nonanol-5-methyl-5-methacrylate and is a volatile substance in the endophyte MC_25L of orange leaves.
-
Description5-methylnonan-5-ol (5-methyl-5-nonanol) is an intermediate in the production of 5-nonanol-5-methyl-5-methacrylate and is a volatile substance in the endophyte MC_25L of orange leaves.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number33933-78-7
-
Formula Weight158.28
-
Molecular FormulaC10H22O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(C)(CCCC)CCCC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
ACTH 11-24
ACTH (11-24) is a fragment of adrenocorticotrophin, induces cortisol release. ACTH (11-24) has been identified as a competitive antagonist of ACTH (1-39) and ACTH (1-10) in isolated adrenal cells.
-
6,7-Dimethoxy-2-[2-(...
NF-κB-IN-13 (compound 12) can significantly inhibit LPS-induced NF-κB activation and NO production in RAW264.7 macrophages. NF-κB-IN-13 has anti-inflammatory effects.
-
Disitamab vedotin
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker.
